#2469 - Brigham Buhler

The Biden Administration has stirred controversy by labeling peptides as dangerous, despite the lack of safety data—a move that has prompted calls for clarification and reclassification.

Biden Administration Labels Peptides Dangerous Despite Lacking Safety Data

Foia Requests to FDA For Decision Clarity Unanswered

Brigham Buhler has raised concerns about the recent ban on peptides under the Biden administration, despite the existence of over 800 studies vouching for the safety of the 19 banned peptides. These studies were submitted to the FDA, but the ban persists. Previously, the FDA under the prior administration had already classified peptides as dangerous. Buhler, seeking transparency, submitted 17 FOIA requests to the FDA for more information on the rationale behind labeling peptides as dangerous, but none of these requests received a response.

Push for Administration to Restore Peptide Access

Buhler Hopeful Biden, Kennedy Will Reclassify Peptides For Access

Buhler further discusses the role of pharmaceutical industry lobbying in attempting to reclassify peptides as biologics. ...

The discussion with Joe Rogan and Brigham Buhler sheds light on the differences between peptides and pharmaceutical drugs regarding efficacy, safety, and regulatory standards.

Peptides Significantly Improve Health and Vitality For Millions

Joe Rogan and Brigham Buhler talked about the transformative effects of peptides on the health and vitality of numerous individuals. These peptides, Buhler insists, are not pseudoscience but based on their tangible health benefits. He cites examples, including his personal experience with Dihexa, which improved his neurocognitive function, and the story of Jelly, previously 500 pounds, who now runs and engages in active hobbies. Buhler stresses the role of real-time health metrics tracking in evaluating the effectiveness of peptides.

Peptide-Cancer Link Rooted In Flawed 1930s Study

Buhler debunks a common misconception that [restricted term] therapy leads to prostate cancer, which originates from a flawed study in the 1930s involving only three patients. New evidence suggests that optimal levels of [restricted term] might actually provide protection against several forms of cancer. He also details how this fallacy has persisted in the medical community, despite the FDA considering label changes that reflect newer understandings regarding [restricted term] and hormones.

Pharmaceutical Drugs Still Approved Despite Label Changes or Recalls

Buhler reveals that a significant number of FDA-approved drugs undergo major label changes or recalls. Using an ...

The healthcare system faces criticism for focusing on monetizing chronic disease rather than promoting preventative and personalized care. Brigham Buhler discusses the desire to shift towards innovation in treatment despite the system’s constraints.

Healthcare System Prioritizes Monetizing Chronic Disease Over Preventative, Personalized Care

Buhler criticizes the healthcare system for managing symptoms of chronic disease for profit, often through prescription management, rather than promoting health. He contrasts this with longevity-based clinics that conduct thorough diagnostics to address issues like hormonal imbalances and obesity. Buhler also mentions the influence of special interests on the healthcare system, which leads to catastrophic effects on national health and security. Joe Rogan agrees that the current profitable system faces resistance to change.

Benefits Pharma and Insurance, Not Patients

The speakers agree that the current healthcare system, also referred to as the "sick care system," primarily benefits pharmaceutical companies and the insurance industry at the expense of patients. As evidence, Buhler points to the United States' high rates of chronic disease and healthcare expenditure while emphasizing the need for a focus on healthspan.

Peptides, Stem Cells, Gene Therapies Face Regulatory Hurdles

Buhler contends with complex regulatory processes that hinder innovative treatments. He argues peptides have been wrongly labeled as dangerous and discusses the conflict within the industry, such as Eli Lilly lobbying against peptide use while making business moves in the peptide market.

Buhler Proposes Direct Patient Access to Treatments Without Insurance or Government Approval

Advocating for a shift to personalized medicine without the mandate of Medicare, Medicaid, or federal government, Buhler proposes that patients have direct access to treatments like peptides and stem cells. He insists on leveraging technology like large language models and wearables to pre ...

Emerging medical technologies, particularly in stem cell research and genetic medicine, are set to revolutionize the future of healthcare.

Discovery of Rare, Promising "Muse" Stem Cells

Brigham Buhler discusses a rare subset phenotype of stem cell called "Muse" cells, which stands for multi-lineage stress-enduring. Discovered by Mari Dozawa when she found they survived overnight outside of cryopreserve, these cells comprise less than 2% of stem cells and exhibit unique qualities. Muse cells are a scientific breakthrough, being both pluripotent and non-tumorigenic. Unlike traditional mesenchymal stem cells (MSCs), which only signal damage and transfer mitochondria without differentiating, Muse cells can differentiate into any cell type and are naturally occurring in the human body.

Pluripotency is a key property of Muse cells, allowing them to differentiate into various cell types and match the phenotype of damaged cells they encounter. The cells can navigate and modulate the immune system. Buhler cites studies where Muse cells demonstrated immunomodulatory abilities, as well as high engraftment rates. Muse cells also possess the capability of homing in on damaged cells, absorbing them, and converting into young, healthy versions of those cells, acting with high precision and rapid effectiveness.

Muse cells are already being used proactively and preventatively in countries like Japan and Dubai, showing promising results. For example, children born with encephalitis treated with Muse cells within eight days of birth had normal brain function. Moreover, Muse cells are being integrated into treatments available in Florida, Texas, and Arizona, and boast a significant benefit to mitochondrial function. Their potential in regenerative medicine is significant due to their ability to survive stress conditions without cryopreservation and their inherent regenerative capabilities.

Muse Cells: Pluripotent, Non-tumorigenic, With Homing and Immunomodulatory Properties

Muse cells are considered safe, never turning into tumors in studies, and in trials with mice with pre-existing cancer, the tumors often shrank or did not grow worse. Their homing abilities allow them a much higher engraftment rate to the site of damage compared to traditional MSCs.

Buhler highlights the pluripotency, safety, and homing properties that make Muse cells a game-changer in medical treatments. These cells are pliable and ready to be programmed into specific cell types before administration to the body, offering a plethora of treatment opportunities.

Genetic Research: Activating Beneficial Genes for Future Medicine

On the front of genetic medicine, Buhler discusses the potential of genetics to revolutionize healthcare. He points out that the field is in its infancy, but genetic research is becoming increasingly relevant in personalizing medicine. He talks about gene markers, like P452, that respond to treatment and improve aspects like sleep, hinting at the future of tailored healthcare.

Buhler mentions the integration of gene sequencing into an upcoming app, emphasizing the importance of understanding one's genet ...